Retrospective studies in scleroderma: skin response to potassium para-aminobenzoate therapy.
Analyses were made of University of Michigan Hospital records of 467 patients diagnosed during the period 1948 - July 1980 as having scleroderma (390) or scleroderma associated with manifestations of other collagen disease (77). In all, there were coded 4733 visits or admissions. Demographic characteristics are detailed for the 390 patients with clinical features of scleroderma alone. The principal focus of this report is on degree and extent of skin involvement and response to therapy with potassium para-aminobenzoate (Potaba, KPAB). Ninety percent of 224 patients treated with KPAB experienced mild, moderate, or marked skin softening. Among a parallel group of 96 evaluable patients who did not receive KPAB, less than 20% were noted to have mild or moderate skin improvement at the end of follow-up. The difference in skin softening attained by patients treated with KPAB compared to that of patients who did not receive this medication was significant (p less than 0.0001).
Zarafonetis
C J
CJ
Department of Internal Medicine, University of Michigan Medical School, Ann Arbor.
Dabich
L
L
Skovronski
J J
JJ
DeVol
E B
EB
Negri
D
D
Yuan
W
W
Wolfe
R
R
D062365:Aminobenzoates / Q000627:therapeutic use*; D006801:Humans; D012189:Retrospective Studies; D012595:Scleroderma, Systemic / Q000188:drug therapy* / Q000503:physiopathology; D012867:Skin / Q000187:drug effects*
D062365:Aminobenzoates